Leqembi Iqlik lets patients self-administer anti-amyloid drug in about 15 seconds, cutting out the IV chair treatment used to require.
For the past two years, staying on Leqembi has meant a recurring appointment nobody looks forward to: an IV chair, a drip line and an hour or more of watching a bag empty, every two weeks, for a drug that has to be taken consistently to work. Multiply that by however many months of treatment a person needs, and the logistics alone become a genuine barrier, especially for older patients, for caregivers juggling work and appointments and for anyone who lives an hour from the nearest infusion center.
That barrier just got smaller. On 24 August, BioArctic and its partner Eisai announced that Leqembi Iqlik, a subcutaneous, autoinjector version of the Alzheimer’s drug lecanemab, is now available in the US for initiation therapy, on the heels of its FDA approval on 13 July [1]. It’s the first anti-amyloid treatment cleared for at-home dosing at both the start of treatment and throughout maintenance.
Fifteen seconds instead of an afternoon
The mechanics are almost anticlimactic in how simple they are. The starting dose is 500 milligrams, delivered as two 250-milligram injections, each taking roughly 15 seconds through an autoinjector. Compare that with the IV version, which requires a clinical setting, trained staff to manage the infusion and enough time carved out of a day to sit through it.
Iqlik doesn’t eliminate medical oversight entirely; MRI monitoring is still required before starting treatment and at specific points afterward, to watch for a known side effect called ARIA, a type of brain swelling or bleeding that anti-amyloid drugs carry a risk for. But the day-to-day burden of taking the drug drops enormously.
It’s easy to treat a delivery-method change as a footnote to the “real” news of a drug’s approval, but for a chronic, long-duration treatment, the format is arguably half the story. Drugs that require frequent clinic visits quietly lose patients over time, not because the science stops working, but because life gets in the way of the logistics.
An autoinjector that a patient or a caregiver can use at home, in the same way people already manage insulin or certain arthritis medications, removes a huge chunk of that friction. It also frees up infusion center capacity for other patients, which becomes a real bottleneck as more people get diagnosed earlier thanks to tools like blood-based amyloid testing.
Where lecanemab sits in the bigger picture
Leqembi is lecanemab, an antibody that targets clumped forms of amyloid-beta in the brain, and BioArctic describes it as the world’s first drug proven to slow the progression of Alzheimer’s disease and reduce cognitive impairment in its early stages. It’s now approved in 53 countries, with the subcutaneous formulation working through regulatory review in several more, including Japan and China, where a Biologics License Application was accepted this January and given priority review status the following month.
The drug’s development has run alongside a long list of ongoing trials that stretch its relevance well past the patients already diagnosed. The AHEAD 3-45 study, a four-year public-private trial involving Eisai, Biogen and the Alzheimer’s Clinical Trial Consortium, is testing lecanemab in people who are cognitively normal but already show elevated amyloid in the brain – essentially asking whether treating the disease before symptoms appear at all can change its course entirely.
A separate study, Tau NexGen, is using lecanemab as a backbone therapy for a rare inherited form of the disease.
A treatment that fits into a life, not around it
BioArctic, founded on research into neurodegenerative disease, has built its identity around drugs that “delay or stop the progression” of conditions like Alzheimer’s, Parkinson’s and ALS, the company’s proprietary BrainTransporter technology is aimed at getting antibodies across the blood-brain barrier more efficiently for exactly this kind of work. However, a drug’s effectiveness in a trial and its effectiveness in someone’s actual life are two different questions, and adherence is where a lot of promising longevity-relevant treatments quietly fail.
A once-weekly injection a caregiver can administer at the kitchen table, instead of a biweekly trip to an infusion suite, is the kind of unglamorous change that determines whether a scientifically sound treatment for cognitive decline actually gets taken consistently enough to protect the years of independence and clarity it’s designed to preserve.
Image courtesy of Eisai
[1] https://www.bioarctic.com/en/leqembi-iqlik-for-initiation-treatment-launched-in-the-us/
